BRCA2 GENE MUTATION
Clinical trials for BRCA2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new BRCA2 GENE MUTATION trials appear
Sign up with your email to follow new studies for BRCA2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early-phase trial is testing the drug olaparib in 15 people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. The goal is to see if taking olaparib for two cycles can safely shrink tumors and stop them from growing. Olap…
Matched conditions: BRCA2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo targets tough prostate cancer in understudied groups
Disease control TerminatedThis study tested a combination of two drugs (niraparib and abiraterone plus prednisone) for men with metastatic hormone-sensitive prostate cancer that has certain gene mutations. It focused on Hispanic/Latino and Black patients, who are often underrepresented in research. The go…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Qian Qin • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New hope for tough cancers: drug targets BRCA mutations
Disease control OngoingThis study tests a drug called talazoparib in people with advanced cancers that have not responded to standard treatments. The drug works by blocking an enzyme that helps cancer cells survive, especially in tumors with changes in the BRCA genes or related DNA repair genes. The go…
Matched conditions: BRCA2 GENE MUTATION
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Can diet and exercise programs cut cancer risk? new study tests best approach
Prevention OngoingThis study tests different programs to help people at high risk for cancer eat healthier and exercise more. The goal is to see which approach works best to increase physical activity and improve diet. About 337 people with a high BMI, low activity, or poor diet are taking part. T…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated May 04, 2026 16:31 UTC
-
Genetic counseling by phone may ease cancer fears in High-Risk women
Knowledge-focused TerminatedThis study looks at whether watching an online genetics video, with or without phone counseling, helps reduce stress about cancer risk in women with triple-negative breast cancer. About 5,200 women aged 30 or older who have at least one ovary and a history of early or triple-nega…
Matched conditions: BRCA2 GENE MUTATION
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC